Pfizer, Covid
Pfizer lifts profit view on cost cuts, demand for COVID products
Pfizer beat first-quarter profit estimates on Wednesday, benefiting from cost cuts and strong sales for its pneumonia and respiratory synctitial virus vaccines.
Pfizer lifts profit forecast on cost cuts, smaller drop in Covid drug demand
Pfizer lifted its annual profit forecast on Wednesday, and reported first-quarter results that topped Wall Street estimates on cost cuts, a smaller-than-feared drop in sales of its COVID antiviral treatment and strong sales of its pneumonia vaccine.
Pfizer lifts 2024 profit view on cost cuts, higher COVID vaccine demand
Pfizer lifted its annual profit forecast on Wednesday, banking on cost cuts and better-than-expected demand for its COVID antiviral treatment and vaccine. The U.S. drugmaker's shares rose nearly 3% before the bell after the company said it
Pfizer beats revenue estimates, raises profit outlook on cost cuts and smaller-than-feared drop in Covid drug sales
The pharmaceutical giant's quarterly results also benefited from a smaller-than-feared drop in sales for its Covid antiviral pill Paxlovid.
Pfizer Profits Drop On Lower Covid-19 Product Sales
Pfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other pharmaceutical areas and implements previously announced cost cuts.
Pfizer Cost Cutting Measures Lead to Rise in Profit Outlook
Pfizer raised its annual profit forecast and reported first-quarter results that exceeded Wall Street’s expectations, driven by cost-cutting measures, resilient sales of its COVID antiviral treatment,
A better COVID treatment for the immunocompromised? Researchers create a non-toxic potential alternative to Paxlovid
A combination of two antiviral compounds may be a promising alternative to Paxlovid when treating COVID-19 in ...
Pfizer Embraces Direct-To-Consumer Model For Covid Antiviral, Says Comirnaty Revenues Continue To Perform Consistently With Expectations
Pfizer Inc. (NYSE:PFE) reported first-quarter adjusted EPS of $0.82, down 33% year over year, beating the consensus of $0.54.
Can nasal Neosporin fight COVID? Surprising new research suggests it works
A potential treatment for COVID-19 may have been hiding in our medicine cabinets, a new study in PNAS has found ...
EurekAlert!14m
Promising new treatment strategy for deadly flu-related brain disorders
Researchers from Osaka University have found that a brain disorder associated with flu (influenza-associated encephalopathy, or IAE) can be caused by the influenza virus entering the brain from the ...
cidrap.umn7d
Data: Optimal initiation of Paxlovid in hospitalized COVID patients is 3 to 5 days
But if Paxlovid is initiated before 3 days, the risk of viral rebound is significantly increased with no improvement in ...
Research highlights best window for paxlovid administration in COVID-19 patients
Researchers have described the optimal timing for COVID-19 patients to take the antiviral, Paxlovid, to get the most benefit ...
Yahoo17h
Pfizer lifts profit forecast as CEO sees reason for optimism in 2024
(Reuters) -Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, boosted by cost cutting efforts and stronger-than-expected sales of ...
Salon4d
Can nasal Neosporin fight COVID? Surprising new research suggests it works
told Salon via email that the research could have broader implications that extend beyond COVID-19. “This could be a potential broad spectrum antiviral treatment and prophylaxis,”Adalja said.
Yahoo Finance1d
Pfizer lifts profit view on cost cuts, smaller drop in demand for COVID products
(Reuters) -Pfizer lifted its annual profit forecast, banking on cost cuts, a smaller-than-feared drop in sales for its COVID ...